Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 163

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Effects of Statin Therapy According to Plasma High-Sensitivity C-Reactive Protein Concentration in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): A Retrospective Analysis

Open access
McMurray, John J.V., Kjekshus, John, Gullestad, Lars, Dunselman, Peter, Hjalmarson, Åke, Wedel, Hans, Lindberg, Magnus, Waagstein, Finn, Grande, Peer, Hradec, Jaromir, Kamenský, Gabriel, Korewicki, Jerzy, Kuusi, Timo, Mach, François, Ranjith, Naresh, Wikstrand, John·2009·Circulation

Abstract

Background— We examined whether the antiinflammatory action of statins may be of benefit in heart failure, a state characterized by inflammation in which low cholesterol is associated with worse outcomes. Methods and Results— We compared 10 mg rosuvastatin daily with placebo in patients with ischemic systolic heart failure according to baseline high sensitivity-C reactive protein (hs-CRP) <2.0 mg/L (placebo, n=779; rosuvastatin, n=777) or ≥2.0 mg/L (placebo, n=1694; rosuvastatin, n=1711). The primary outcome was cardiovascular death, myocardial infarction, or stroke. Baseline low-density lipoprotein was the same, and rosuvastatin reduced low-density lipoprotein by 47% in both hs-CRP groups. Median hs-CRP was 1.10 mg/L in the lower and 5.60 mg/L in the higher hs-CRP group, with higher hs-CRP associated with worse outcomes. The change in hs-CRP with rosuvastatin from baseline to 3 months was −6% in the low hs-CRP group (27% with placebo) and −33.3% in the high hs-CRP group (−11.1% with placebo). In the high hs-CRP group, 548 placebo-treated (14.0 per 100 patient-years of follow-up) and 498 rosuvastatin-treated (12.2 per 100 patient-years of follow-up) patients had a primary end point (hazard ratio of rosuvastatin to placebo, 0.87; 95% confidence interval, 0.77 to 0.98; P =0.024). In the low hs-CRP group, 175 placebo-treated (8.9 per 100 patient-years of follow-up) and 188 rosuvastatin-treated (9.8 per 100 patient-years of follow-up) patients experienced this outcome (hazard ratio, 1.09; 95% confidence interval, 0.89 to 1.34; P >0.2; P for interaction=0.062). The numbers of deaths were as follows: 581 placebo-treated (14.1 per 100 patient-years of follow-up) and 532 rosuvastatin-treated (12.6 per 100 patient-years) patients in the high hs-CRP group (hazard ratio, 0.89; 95% confidence interval, 0.79 to 1.00; P =0.050) and 170 placebo-treated (8.3 per 100 patient-years) and 192 rosuvastatin-treated (9.7 per 100 patient-years) patients in the low hs-CRP group (hazard ratio, 1.17; 95% confidence interval, 0.95 to 1.43; P =0.14; P for interaction=0.026). Conclusion— In this retrospective hypothesis-generating study, we found a significant interaction between hs-CRP and the effect of rosuvastatin for most end points whereby rosuvastatin treatment was associated with better outcomes in patients with hs-CRP ≥2.0 mg/L. Clinical Trial Registration Information— URL: http://www.clinicaltrials.gov. Unique identifier: NCT00206310.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1161/circulationaha.109.849117

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Research works printed but not linked: 17

  1. 10.1038/nrd1901 · DOI · Paper page
  2. 10.1016/j.tcm.2005.07.002 · DOI
  3. 10.1161/01.atv.0000163840.63685.0c · DOI · Paper page
  4. 10.1161/circ.98.9.839 · doi:10.1161/circ.98.9.839
  5. 10.1136/hrt.66.5.356 · DOI · Paper page
  6. 10.1016/S0735-1097(99)00600-2 · DOI · Paper page
  7. 10.1080/07853890510007232 · DOI · Paper page
  8. 10.1016/j.ahj.2005.06.046 · DOI · Paper page
  9. 10.1161/circulationaha.107.759191 · DOI · Paper page
  10. 10.1016/S0735-1097(00)00745-2 · DOI
  11. 10.1161/circulationaha.104.508465 · DOI · Paper page
  12. 10.1054/jcaf.2002.0804216 · DOI · Paper page
  13. 10.1016/j.jacc.2003.07.016 · DOI · Paper page
  14. 10.1016/S0735-1097(02)01827-2 · DOI
  15. 10.1111/j.1527-5299.2007.07211.x · DOI
  16. 10.1016/j.ejheart.2005.09.005 · DOI
  17. 10.1161/01.cir.0000100688.17280.e6 · DOI · Paper page

Cited by

See all 163

Metadata

Authors
McMurray, J. J. V., Kjekshus, J., Gullestad, L., Dunselman, P., Hjalmarson, A., Wedel, H., Lindberg, M., Waagstein, F., Grande, P., Hradec, J., Kamenský, G., Korewicki, J., Kuusi, T., Mach, F., Ranjith, N., & Wikstrand, J.
Venue
Circulation
Published
2009-12
Volume
120
Issue
22
Pages
2188-2196
ISSN
  • 0009-7322 (ISSN-L)
  • 1524-4539
OpenAlex
W2102754127
Cited by
163
References
8
FWCI
21.22
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effects of Statin Therapy According to Plasma High-Sensitivity C-Reactive Protein Concentration in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): A Retrospective Analysis. https://app.cochat.ai/papers/10.1161/circulationaha.109.849117
The paper
McMurray, J. J. V., Kjekshus, J., Gullestad, L., Dunselman, P., Hjalmarson, A., Wedel, H., Lindberg, M., Waagstein, F., Grande, P., Hradec, J., Kamenský, G., Korewicki, J., Kuusi, T., Mach, F., Ranjith, N., & Wikstrand, J. (2009). Effects of Statin Therapy According to Plasma High-Sensitivity C-Reactive Protein Concentration in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): A Retrospective Analysis. Circulation. https://doi.org/10.1161/circulationaha.109.849117

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.